Avid Bioservices Inc (CDMO)

[biopharm]

besides blocking just PS binding to its receptors on immune cells, there is an FC- FC gamma -based effector function leading to ADCC and so on and so forth - an immune effector function that other checkpoint inhibitors do not have blocking PD-1 or blocking CTLA-4. So, you’ve got a component here that is beyond other checkpoint inhibitors, that brings in an effector function that others do not have. Looking at that aspect or looking at some of the translational data, do you think that beyond the PD-1, PD-L1 non-immunogenic tumors, there is a possibility that PS blockade will have far more effect potentially driving [ph??] antigen presentation. Any comments on that?” ..

Rahul was with Noble Life Science Partners...and that question directed towards Peregrine Pharmaceuticals was an errand opener for some ...

To Infinity and Beyond is where Avid Bioservices CDMO will be going ....remember, Ampersand did not just get involved with just a pure play CDMO...as some like to portray

Interesting where Rahul ended up....actually, more interesting where ALL INVOLVED ended up ..signing dozens of NDAs non disclosure agreements

Alex Azar...how much in the coffers just to have DHHS do a little investment or maybe Merck would not like such an idea?